Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial


Middleton, Gary, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Greenhalf, William, Ghaneh, Paula, Jackson, Richard, Cox, Trevor, Evans, Anthony ORCID: 0000-0001-8547-1730, Shaw, Victoria E ORCID: 0000-0002-0429-0186, Wadsley, Jonathan, Valle, Juan W et al (show 14 more authors) (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18 (4). 486 - 499.

[img] Text
C:\Data\Papers\VIP\ViP Manuscript.docx - Submitted Version
Download (158kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 22 Sep 2017 08:14
Last Modified: 13 Jan 2021 08:17
DOI: 10.1016/S1470-2045(17)30084-0
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3009559
Dimensions
Altmetric
CORE (COnnecting REpositories)